Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo aberto comparando AAA817 versus padrão de tratamento no tratamento de adultos com mCRPC positivo para PSMA previamente tratados que apresentam progressão da doença durante ou após terapia direcionada a [177Lu] Lu-PSMA (PSMAcTION)

19 de setembro de 2026 atualizado por: Novartis Pharmaceuticals

PSMAcTION: Um estudo de fase II/III, aberto, internacional, multicêntrico, randomizado de AAA817 versus padrão de tratamento no tratamento de participantes adultos com câncer de próstata metastático resistente à castração positivo para PSMA que progrediu em ou após [177Lu] Lu-PSMA Terapia direcionada

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy.

Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment

Visão geral do estudo

Descrição detalhada

Study CAAA817A12201 consists of 2 parts: a randomized, open-label, international, multicenter, phase II study (Phase II) to collect more information to support the proposed dose of AAA817 and a randomized, open-label, international, multicenter, 2- arm phase III study (Phase III) aimed to evaluate the efficacy and safety of proposed dose of AAA817 vs. investigator's choice of standard of care (SoC) in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had treatments with ARPI and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy. The purpose of the phase II part (Phase II) of this study is to collect additional information to support proposed phase III dose of AAA817.

Tipo de estudo

Intervencional

Inscrição (Estimado)

443

Estágio

  • Fase 2
  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: Novartis Pharmaceuticals
  • Número de telefone: +41613241111

Locais de estudo

    • New South Wales
      • Darlinghurst, New South Wales, Austrália, 2010
        • Recrutamento
        • Novartis Investigative Site
    • Queensland
      • Herston, Queensland, Austrália, 4029
        • Recrutamento
        • Novartis Investigative Site
    • Victoria
      • Melbourne, Victoria, Austrália, 3004
        • Recrutamento
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brasil, 01308-050
        • Recrutamento
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 05652-000
        • Recrutamento
        • Novartis Investigative Site
      • Beijing, China, 100036
        • Recrutamento
        • Novartis Investigative Site
      • Beijing, China, 100034
        • Recrutamento
        • Novartis Investigative Site
      • Guangzhou, China, 510060
        • Recrutamento
        • Novartis Investigative Site
      • Shanghai, China, 200025
        • Recrutamento
        • Novartis Investigative Site
      • Shanghai, China, 200032
        • Recrutamento
        • Novartis Investigative Site
      • Tianjin, China, 300480
        • Recrutamento
        • Novartis Investigative Site
      • Tianjin, China, 300300
        • Recrutamento
        • Novartis Investigative Site
    • Fujian
      • Fuzhou, Fujian, China, 350025
        • Recrutamento
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Recrutamento
        • Novartis Investigative Site
      • Wuhan, Hubei, China, 430030
        • Recrutamento
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, China, 210006
        • Recrutamento
        • Novartis Investigative Site
      • Nanjing, Jiangsu, China, 210029
        • Recrutamento
        • Novartis Investigative Site
    • Liaoning
      • Shenyang, Liaoning, China, 110011
        • Recrutamento
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, China, 710032
        • Recrutamento
        • Novartis Investigative Site
      • Xian, Shanxi, China, 710061
        • Recrutamento
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Recrutamento
        • Novartis Investigative Site
      • Singapore, Cingapura, 119228
        • Recrutamento
        • Novartis Investigative Site
      • Singapore, Cingapura, 168583
        • Recrutamento
        • Novartis Investigative Site
      • Singapore, Cingapura, 258499
        • Recrutamento
        • Novartis Investigative Site
      • Seoul, Coréia do Sul, 03080
        • Recrutamento
        • Novartis Investigative Site
      • Seoul, Coréia do Sul, 05505
        • Recrutamento
        • Novartis Investigative Site
      • Seoul, Coréia do Sul, 06591
        • Recrutamento
        • Novartis Investigative Site
      • Seoul, Coréia do Sul, 03722
        • Recrutamento
        • Novartis Investigative Site
    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85258
        • Recrutamento
        • Honor Health Research Institute
        • Investigador principal:
          • Michael Gordon
        • Contato:
    • California
      • Los Angeles, California, Estados Unidos, 90073
        • Recrutamento
        • VA Greater LA Healthcare System
        • Contato:
        • Investigador principal:
          • Gholam Reza Berenji
      • Palo Alto, California, Estados Unidos, 94304-1207
        • Recrutamento
        • VA Palo Alto Health Care System
        • Investigador principal:
          • Minal Vasanawala
        • Contato:
      • Palo Alto, California, Estados Unidos, 94304
        • Recrutamento
        • Stanford University Medical Center
        • Investigador principal:
          • Hong Song
        • Contato:
      • Santa Barbara, California, Estados Unidos, 93105
        • Recrutamento
        • Sansum Clinic
        • Investigador principal:
          • Gregg Newman
        • Contato:
      • Santa Monica, California, Estados Unidos, 90404
        • Recrutamento
        • Saint Johns Cancer Institute
        • Investigador principal:
          • Przemyslaw Twardowski
        • Contato:
    • Colorado
      • Denver, Colorado, Estados Unidos, 80218
        • Recrutamento
        • Rocky Mountain Cancer Centers
        • Investigador principal:
          • Manojkumar Bupathi
        • Contato:
    • Connecticut
      • Hartford, Connecticut, Estados Unidos, 06102
    • Florida
      • Miami, Florida, Estados Unidos, 33173
      • Orlando, Florida, Estados Unidos, 32804
        • Recrutamento
        • AdventHealth
        • Investigador principal:
          • Ravi Shridhar
        • Contato:
    • Georgia
      • Athens, Georgia, Estados Unidos, 30607
        • Recrutamento
        • University Cancer and Blood Center LLC
        • Contato:
        • Investigador principal:
          • Petros Nikolinakos
      • Atlanta, Georgia, Estados Unidos, 30322
        • Recrutamento
        • Emory University
        • Investigador principal:
          • Shahid Sattar Ahmed
        • Contato:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • University of Chicago
        • Investigador principal:
          • Mohammad Atiq
        • Contato:
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Recrutamento
        • Indiana University
        • Investigador principal:
          • Nabil Adra
        • Contato:
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Recrutamento
        • University of Kansas Hospital
        • Investigador principal:
          • Xinglei Shen
        • Contato:
    • Louisiana
      • Metairie, Louisiana, Estados Unidos, 70006
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Recrutamento
        • Beth Israel Deaconess Medical Center
        • Investigador principal:
          • David J Einstein
        • Contato:
      • Boston, Massachusetts, Estados Unidos, 02115
        • Recrutamento
        • Dana Farber Cancer Institute
        • Investigador principal:
          • Xiao Wei
        • Contato:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Recrutamento
        • WA Uni School Of Med
        • Investigador principal:
          • Jeff Michalski
        • Contato:
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68154
        • Recrutamento
        • Nebraska Cancer Specialists
        • Investigador principal:
          • Samuel Mehr
        • Contato:
    • New Jersey
      • Voorhees Township, New Jersey, Estados Unidos, 08043
        • Recrutamento
        • New Jersey Urology LLC
        • Contato:
        • Investigador principal:
          • Gordon Brown
    • New York
      • New York, New York, Estados Unidos, 10029
        • Recrutamento
        • Mount Sinai Hosp Med School
        • Investigador principal:
          • Randy Yeh
        • Contato:
      • Syracuse, New York, Estados Unidos, 13210
        • Recrutamento
        • Associated Med Professionals of NY
        • Investigador principal:
          • Steven Finkelstein
        • Contato:
      • The Bronx, New York, Estados Unidos, 10467
        • Recrutamento
        • Montefiore Medical Center
        • Investigador principal:
          • Benjamin A Gartrell
        • Contato:
    • Ohio
      • Gahanna, Ohio, Estados Unidos, 43230
        • Recrutamento
        • Central Ohio Urology Group
        • Investigador principal:
          • Benjamin Martin
        • Contato:
    • Oregon
      • Springfield, Oregon, Estados Unidos, 97477
        • Recrutamento
        • Oregon Urology Institute
        • Investigador principal:
          • Bryan Mehlhaff
        • Contato:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19111
        • Recrutamento
        • Fox Chase Cancer Center
        • Contato:
        • Investigador principal:
          • Matthew Zibelman
    • South Carolina
      • Myrtle Beach, South Carolina, Estados Unidos, 29572
        • Recrutamento
        • Carolina Urologic Research Center
        • Investigador principal:
          • Neal D Shore
        • Contato:
    • Texas
      • Dallas, Texas, Estados Unidos, 75251
        • Recrutamento
        • Texas Oncology
        • Contato:
        • Investigador principal:
          • Michael P Herman
      • San Antonio, Texas, Estados Unidos, 78229
    • Utah
      • Murray, Utah, Estados Unidos, 84107
        • Recrutamento
        • Utah Intermountain Medical Center
        • Investigador principal:
          • David Gill
        • Contato:
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
      • Roanoke, Virginia, Estados Unidos, 24014
        • Recrutamento
        • Onco Hemato Asso of SW Virginia
        • Investigador principal:
          • David Buck
        • Contato:
    • Washington
      • Seattle, Washington, Estados Unidos, 98109-1024
        • Recrutamento
        • Fred Hutchinson Cancer Research Center
        • Contato:
        • Investigador principal:
          • Ruben Raychaudhuri
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Recrutamento
        • Medical College Of Wisconsin
        • Investigador principal:
          • Deepak Kilari
        • Contato:
      • Hong Kong, Hong Kong, 999077
        • Recrutamento
        • Novartis Investigative Site
      • Beersheba, Israel, 8457108
        • Recrutamento
        • Novartis Investigative Site
      • Haifa, Israel, 3109601
        • Recrutamento
        • Novartis Investigative Site
      • Jerusalem, Israel, 9112001
        • Recrutamento
        • Novartis Investigative Site
      • Petah Tikva, Israel, 4941492
        • Recrutamento
        • Novartis Investigative Site
      • Ramat Gan, Israel, 5265601
        • Recrutamento
        • Novartis Investigative Site
      • Tel Aviv, Israel, 6423906
        • Recrutamento
        • Novartis Investigative Site
      • Chiba, Japão, 2608717
        • Recrutamento
        • Novartis Investigative Site
      • Fukuoka, Japão, 8128582
        • Recrutamento
        • Novartis Investigative Site
      • Fukuoka, Japão, 8110213
        • Recrutamento
        • Novartis Investigative Site
      • Fukuoka, Japão, 8120033
        • Recrutamento
        • Novartis Investigative Site
      • Fukushima, Japão, 9601295
        • Recrutamento
        • Novartis Investigative Site
      • Ishikawa, Japão, 9208641
        • Recrutamento
        • Novartis Investigative Site
      • Kyoto, Japão, 6068507
        • Recrutamento
        • Novartis Investigative Site
    • Chiba
      • Kashiwa, Chiba, Japão, 2778577
        • Recrutamento
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, Japão, 0608648
        • Recrutamento
        • Novartis Investigative Site
    • Hyōgo
      • Kobe, Hyōgo, Japão, 6500047
        • Recrutamento
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japão, 2360004
        • Recrutamento
        • Novartis Investigative Site
    • Kuala Lumpur
      • Putrajaya, Kuala Lumpur, Malásia, 62250
        • Recrutamento
        • Novartis Investigative Site
    • Selangor
      • Petaling Jaya, Selangor, Malásia, 46050
        • Recrutamento
        • Novartis Investigative Site
      • Petaling Jaya, Selangor, Malásia, 46150
        • Recrutamento
        • Novartis Investigative Site
      • Huxquilucan, México, 52763
        • Recrutamento
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, México, 14050
        • Recrutamento
        • Novartis Investigative Site
      • Basel, Suíça, 4031
        • Recrutamento
        • Novartis Investigative Site
      • Bellinzona, Suíça, 6500
        • Recrutamento
        • Novartis Investigative Site
      • Bern, Suíça, 3010
        • Recrutamento
        • Novartis Investigative Site
      • Taipei, Taiwan, 10002
        • Recrutamento
        • Novartis Investigative Site
      • Taipei, Taiwan, 11217
        • Recrutamento
        • Novartis Investigative Site
      • Taipei, Taiwan, 103616
        • Recrutamento
        • Novartis Investigative Site
      • Taoyuan, Taiwan, 33305
        • Recrutamento
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 100 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria: ∙

  • adults ≥ 18 years of age.
  • ECOG performance status of 0 to 2.
  • histopathological and/or cytological confirmation of adenocarcinoma of the prostate.
  • PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imaging agent as protocol instructed,
  • castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
  • Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy, and progressed on or after [177Lu]Lu-PSMA targeted therapy.
  • ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization
  • eGFR as requested by the sponsor

Exclusion Criteria:

  • Any investigational agents within 28 days prior to the day of randomization.
  • Any 225Ac-based investigational compound used prior to the day of randomization.
  • Participants with a history of CNS metastases who are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity.
  • Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days) or chronic kidney disease (at least 3 months of ongoing renal injury)
  • Baseline xerostomia ≥ Grade 2 by CTCAE v.5
  • History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/or clinically active significant cardiac disease
  • History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 2 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, non-invasive malignant colon polyps that have been removed).

Other protocol-defined inclusion/exclusion criteria may apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Phase II: AAA817 Dose B

AAA817 will be given for a number of cycles; a cycle = 8 weeks

The investigational treatment is AAA817

Outros nomes:
  • [225Ac]Ac-PSMA-617)

Investigational treatment is the Dose B of AAA817

Outros nomes:
  • [225Ac]Ac-PSMA-617
Comparador Ativo: Phase III: Investigator's choice of SoC

Participants will be given Standard of Care (SOC) treatment per Investigator's choice.

The control treatment in Phase III is investigator's choice of SoC

Experimental: Phase II: AAA817 Dose A

AAA817 Dose A will be given for a number of cycles: a cycle = 8 weeks

The investigational treatment is AAA817

Outros nomes:
  • [225Ac]Ac-PSMA-617)

Investigational treatment is the Dose B of AAA817

Outros nomes:
  • [225Ac]Ac-PSMA-617
Experimental: Phase III: Recommended Phase 3 Dose of AAA817

Rp3D of AAA817 will be given for a number of cycles; a cycle = 8 weeks

The investigational treatment is AAA817

Outros nomes:
  • [225Ac]Ac-PSMA-617)

Investigational treatment is the Dose B of AAA817

Outros nomes:
  • [225Ac]Ac-PSMA-617

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Biochemical response rate (Phase II)
Prazo: from date of randomization up to approximately 24 months

Biochemical response rate as defined as the percentage of participants who achieved a ≥ 50% decrease from baseline that is confirmed by a second measurement

from date of randomization up to approximately 24 months
Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II
Prazo: from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later

Safety defined as the type, incidence and severity of AEs and SAEs, and deaths

from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later
Tolerability of the proposed dose of AAA817- Phase II
Prazo: From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817

Percentage of participants who experienced Dose interruptions, reductions, discontinuation, dose intensity and duration of exposure

From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817
Radiographic progression-free survival (rPFS)- Phase III
Prazo: from date of randomization up to approximately 24 months

Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis

from date of randomization up to approximately 24 months
Overall survival (OS)- Phase III
Prazo: from date of randomization up to approximately 24 months

Percentage of participants who are alive or who are lost to follow-up at the time of analysis

from date of randomization up to approximately 24 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Radiographic progression-free survival (rPFS)- Phase II
Prazo: from date of randomization up to approximately 24 months

Percentage of participants who are alive without radiographic progression or who are lost to follow-up at the time of analysis

from date of randomization up to approximately 24 months
Progression free survival (PFS)- Phase II
Prazo: from date of randomization up to approximately 24 months

Percentage of Participants meeting Progression Free Survival

from date of randomization up to approximately 24 months
Overall response rate (ORR)- Phase II
Prazo: from date of randomization up to approximately 24 months

Percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR)

from date of randomization up to approximately 24 months
Disease control rate (DCR)- Phase II
Prazo: from date of randomization up to approximately 24 months

Percentage of participants with BOR of CR, PR, stable disease (SD) or non-CR/non-PD

from date of randomization up to approximately 24 months
Overall survival (OS)- Phase II
Prazo: from date of randomization up to approximately 24 months

Percentage of participants who are alive or who are lost to follow-up at the analysis data cut-off

from date of randomization up to approximately 24 months
Progression free survival (PFS) -Phase III
Prazo: from date of randomization up to approximately 24 months

Percentage of participants with PFS -defined as the time from date of randomization to first documented progression

from date of randomization up to approximately 24 months
Overall response rate (ORR)- Phase III
Prazo: from date of randomization up to approximately 24 months

ORR is defined as the percentage of participants with best overall response (BOR) of confirmed complete response (CR) or partial response (PR)

from date of randomization up to approximately 24 months
Disease control rate (DCR) -Phase III
Prazo: from date of randomization up to approximately 24 months

DCR is defined as the percentage of participants with BOR of confirmed CR, PR, stable disease (SD) or Non-CR/Non progressive disease (PD)

from date of randomization up to approximately 24 months
Duration of response (DoR)- Phase III
Prazo: from date of randomization up to approximately 24 months

Percentage of participants with confirmed DoR defined as duration of time between the date of first documented response (CR or PR) and progression or death due to any cause, whichever occurs first.

from date of randomization up to approximately 24 months
Time to first radiographic soft tissue progression (TTSTP)- Phase III
Prazo: from date of randomization up to approximately 24 months

Percentage of participants with confirmed first radiographic progression in soft tissue

from date of randomization up to approximately 24 months
First symptomatic skeletal event (TTSSE)_Phase III
Prazo: from date of randomization up to approximately 24 months

Percentage of participants with confirmed skeletal event is defined as new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, or requirement for radiation therapy to relieve bone pain, or death due to any cause, whichever occurs first

from date of randomization up to approximately 24 months
Prostate specific antigen (PSA) response -Phase III
Prazo: from date of randomization up to approximately 24 months

PSA50 is defined as the percentage of participants who achieved a confirmed ≥ 50% decrease from baseline

from date of randomization up to approximately 24 months
Patient reported disease related symptoms and health-related quality of life (HRQoL): Phase III
Prazo: from date of randomization up to approximately 24 months

Percentage of participants who had a Change from baseline on FACT-P Prostate Cancer Subscale (PCS)

from date of randomization up to approximately 24 months
Time to worsening on the Worst Pain: Phase III
Prazo: from date of randomization up to approximately 24 months

Time to worsening on the Worst Pain defined as the time from randomization to the first occurrence of worsening on the Worst Pain item (brief pain inventory - short form (BPI-SF)) of at least 30% of baseline or minimum of 2 points increase from baseline, or death due to any cause, whichever occurs first. BPI-SF is a self-reported questionnaire to evaluate pain intensity (severity) and impact of pain on the participant's daily functioning (interference).

from date of randomization up to approximately 24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

27 de fevereiro de 2025

Conclusão Primária (Estimado)

27 de junho de 2028

Conclusão do estudo (Estimado)

19 de julho de 2033

Datas de inscrição no estudo

Enviado pela primeira vez

17 de dezembro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de janeiro de 2025

Primeira postagem (Real)

17 de janeiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever